First Tracks Biotherapeutics is a clinical-stage company developing antibody drugs that modulate immune pathways in autoimmune and inflammatory disease. Spun out of AnaptysBio, its pipeline includes programs such as an anti-CD122 antagonist and other immunology candidates aimed at conditions including celiac disease and eosinophilic esophagitis. The company focuses on next-generation antibodies rather than commercial products at this stage.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -47.2 | — |
| Q2 2025 | 0 | — | -42.5 | — |
| Q1 2026 | 0 | — | -50.5 | — |
| Q2 2026 | 0 | — | -33.4 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Capital Clean Energy Carriers Corp. (CCEC), Nektar Therapeutics (NKTR), Lucid Group, Inc. (LCID), Kardigan, Inc. (KARD), G-III Apparel Group, Ltd. (GIII), Seneca Foods Corporation (SENEB)